DPG Mitgliedschaft

This block is broken or missing. You may be missing content or you might need to enable the original module.

Keyword: baxalta

News

Shire Mulls Separation of Neurosciences

11.08.2017 - Ireland-domiciled drugmaker Shire is considering splitting off its neuroscience division into a separate, publicly listed company. The move, revealed during its second-quarter...

Topstories

DCAT Week ’16

03.02.2016 - A key upcoming industry event is DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week brings together pharmaceutical and...

News

Shire to Acquire Baxalta for $32 Billion

12.01.2016 - In a deal worth around $32 billion, Irish drug maker Shire – headquartered in Dublin but managed from Boston, Massachusetts – has agreed a takeover of US biopharmaceutical company...

News

Baxalta Gets EU Nod for Hemophilia Treatment

02.12.2015 - US biopharmaceutical company Baxalta has received European marketing approval for its hemophilia treatment Obizur. The drug is said to be the first recombinant porcine sequence...

News

Shire to Buy Biotech Firm Dyax

04.11.2015 - Ireland-based and London-listed drugmaker Shire has agreed what is being called a “defensive” deal to buy US biotech firm Dyax, which has a breakthrough drug said to threaten one...

News

Shire Makes Offer for Baxalta

05.08.2015 - Irish pharmaceutical producer Shire has made an offer to buy US drugmaker Baxalta for around $30 billion in stock. With the bid, Shire is said to be trying to solidify its position...

Ehrenamtliches Engagement

This block is broken or missing. You may be missing content or you might need to enable the original module.